About Us

Neurent Medical is pioneering innovative treatments for chronic inflammatory sino-nasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Neurent’s proprietary NEUROMARK® technology with its unique design and advanced algorithmic control enables physicians to precisely target and safely disrupt multiple underlying nerve branches to alleviate Chronic Rhinitis symptoms and improve patient quality of life. The company is headquartered in Galway, Ireland and has its US offices in Boston, MA.

Brian Shields
Co-founder & CEO
Board Member
View Bio
Declan Daly
Chief Financial Officer
View Bio
Karen Peterson
VP of Clinical, Regulatory & Quality
View Bio
John Peterson
VP of Sales & Marketing
View Bio
Mark Fletcher
Chairman of the Board
Former President, Medtronic Surgical Technologies
View Bio
Justin Lynch
Board Member
Partner & CFO,
Fountain Healthcare Partners
View Bio
Eamon Brady
Board Member
CEO,
WhiteSwell
View Bio
Drew Burdon
Board Member
LSP
View Bio
Gerry Maguire
General Partner
Atlantic Bridge
View Bio

Recent News

Stay up to date with the latest news from Neurent Medical

Neurent Medical Announces New CPT Code® for Chronic Rhinitis Treatment Offering Significant Symptom Improvements

13th November 2023

New CPT Code

New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

21st March 2023

Significant Symptom Improvements

Neurent Medical Receives FDA Clearance for NEUROMARK, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis

18th November 2021

Press release about FDA Clearance